ACE2 News and Research

RSS

Bispecific antibodies neutralize SARS-CoV-2 and its variants

A new bioRxiv preprint study led by Joshua Tan from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, involves generating bispecific antibodies using a new method cross-linking the antibodies with adjacent spike proteins using dual N-terminal domain/receptor binding domain specificity.

7 Apr 2021

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

A team of scientists from the University of California Santa Cruz, USA, recently identified a novel variant (B.1.x) of SARS-CoV-2 that might be circulating in at least 20 US states and six countries globally.

7 Apr 2021

Which SARS-CoV-2 spike mutants can evade T cell immunity?

A new study reports the capability of a new variant of the virus to escape specific cellular immunity, while possessing a higher binding affinity to the host cell binding receptor, the angiotensin-converting enzyme 2 (ACE2).

7 Apr 2021

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

A new study describes the use of a single dose of vaccine based on the viral protein called the receptor-binding domain (RBD) to elicit powerful neutralizing activity against both the Wuhan strain and the most concerning VOC called the South African (SA) strain.

7 Apr 2021

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

Researchers at the Infection Biology Unit, German Primate Center, and the Georg-August-University Göttingen in Germany have found that the B.1.351 and P.1 SARS-CoV-2 variants have the potential to evade therapeutic antibodies or antibodies induced by natural infection or vaccination.

7 Apr 2021

Natural selection and adaptation of SARS-CoV-2 in mammals

Researchers of the Hubei University of Medicine, China, have analyzed several mutations in different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from mammal species that suggest natural selection and host adaptation are occurring in the virus.

6 Apr 2021

Researchers identify a novel SARS-CoV-2 variant (A.VOI.V2) in southern Africa

Scientists recently explored the transmission dynamics of currently circulating variants of SARS-CoV-2 in a southern African country. By analyzing the genomic sequences of these variants, they have identified a novel SARS-CoV-2 variant with multiple spike mutations. They have temporarily designated the variant A.VOI.V2.

6 Apr 2021

CAL20.C SARS-CoV-2 variant skyrocketing in California evades host immune response

In a study published on the bioRxiv* preprint server, researchers report the effect of neutralizing antibodies from recovered patients or mRNA vaccinated individuals on neutralizing this variant.

6 Apr 2021

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

A fascinating new preprint research paper posted to the bioRxiv* server discusses impressively high neutralizing responses elicited with a single dose of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine formulation, which could help turn the tide of the current pandemic if validated.

6 Apr 2021

Research explores sex differences in placental defenses against SARS-CoV-2 infection

A plethora of earlier studies has reported on the differences between the sexes in susceptibility to the currently circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as its severity. A new preprint research paper posted to the bioRxiv* server extends this to the placenta in pregnancy.

6 Apr 2021

South Africa SARS-CoV-2 variant B.1.351 easily escapes Sputnik vaccine

A new preprint research paper posted to the medRxiv* server reports on vaccine resistance data that pushes the end of the pandemic further away.

6 Apr 2021

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server.

5 Apr 2021

Researchers Identify potent small molecule inhibitors against SARS-CoV-2

A team of scientists from the USA and Sweden has recently screened 8 million small molecule inhibitors against SARS-CoV-2.

5 Apr 2021

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants

A research group from the U.S. demonstrated the practicality of a spike display system in order to accelerate vaccine design, but also to swiftly appraise the effects of mutations in emerging strains of the SARS-CoV-2.

5 Apr 2021

Chemical inhibitor can reduce SARS-CoV-2's ability to infect host cell lines

James McKerrow, MD, PhD, dean of the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego, has long studied neglected tropical diseases -- chronic and disabling parasitic infections that primarily affect poor and underserved communities in developing nations.

3 Apr 2021

Study discovers new target on SARS-CoV-2 spike for protective antibodies

Researchers at The Scripps Research Institute, USA, have described a potential target for COVID-19 vaccines. Dubbed as CC40.8 bnAb, it exhibited broad reactivity with human beta coronaviruses.

1 Apr 2021

Glycans influence SARS-CoV-2 spike–ACE2 binding affinity, finds study

A study conducted at the Los Alamos National Laboratory, USA, and Concordia University, Canada, has explored the impact of different types of glycans on the interaction between SARS-CoV-2 spike protein and human ACE2 receptor.

1 Apr 2021

Could a flavonoid found in common fruit and vegetables combat COVID-19?

Researchers in India have gathered and presented a large body of evidence highlight quercetin – a flavonoid molecule found in many common fruits and vegetables – may be developed into drug therapies used to combat COVID-19.

1 Apr 2021

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

New research deals with the development of RBD trimer as a potent target for SARS-CoV-2 subunit vaccines. This study revealed the development of a trimeric RBD subunit vaccine candidate that could induce strong humoral and cellular immune responses in nonhuman primates (NHPs), namely, rhesus macaques.

1 Apr 2021

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants

A recent paper in the journal Nature shows that while earlier lineages do not elicit antibodies capable of efficiently neutralizing the newly emerged South African variant, SARS-CoV-2 501Y.V2 (B.1.351), the converse does occur.

31 Mar 2021

ACE2 News and Research

Bispecific antibodies neutralize SARS-CoV-2 and its variants

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

Which SARS-CoV-2 spike mutants can evade T cell immunity?

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

Natural selection and adaptation of SARS-CoV-2 in mammals

Researchers identify a novel SARS-CoV-2 variant (A.VOI.V2) in southern Africa

CAL20.C SARS-CoV-2 variant skyrocketing in California evades host immune response

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

Research explores sex differences in placental defenses against SARS-CoV-2 infection

South Africa SARS-CoV-2 variant B.1.351 easily escapes Sputnik vaccine

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

Researchers Identify potent small molecule inhibitors against SARS-CoV-2

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants

Chemical inhibitor can reduce SARS-CoV-2's ability to infect host cell lines

Study discovers new target on SARS-CoV-2 spike for protective antibodies

Glycans influence SARS-CoV-2 spike–ACE2 binding affinity, finds study

Could a flavonoid found in common fruit and vegetables combat COVID-19?

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News